The effects of continuous venovenous hemofiltration on coagulation activation

Critical Care

Volumn 10, Issue 5, 2006, Pages

  Bouman, Catherine S C ^a   de Pont, Anne Cornélie J M ^a   Meijers, Joost C M ^a   Bakhtiari, Kamran ^a   Roem, Dorina ^b   Zeerleder, Sacha ^b   Wolbink, Gertjan ^b   Korevaar, Johanna C ^a   Levi, Marcel ^a   de Jonge, Evert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7; CELLULOSE TRIACETATE; KALLIKREIN INHIBITOR; PLASMIN; PROTEIN C; PROTHROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; BLOOD CLOTTING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FILTER REACTOR; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REACTION TIME; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; VASCULAR ACCESS; COHORT ANALYSIS; HEMOFILTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; SURVIVAL RATE;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COHORT STUDIES; FEMALE; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 34447632044     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5080     Document Type: Article

References (26)

1. Uchino S Kellum JA Bellomo R Doig GS Morimatsu H Morgera S Schetz M Tan I Bouman CSC Macedo E Acute renal failure in critically ill patients: A multinational, multicenter study JAMA 2005 294 813-818 10.1001/ jama.294.7.813 16106006
2. Davenport A The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit Am J Kidney Dis 1997 30 S20-S27 9372975
3. Schetz M Anticoagulation in continuous renal replacement therapy Contrib Nephrol 2001 132 283-303 11395897
4. Cardigan RA McGloin H Mackie IJ Machin SJ Singer M Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration Kidney Int 1999 55 1568-1574 10.1046/j.1523-1755.1999.00397.x 10201024
5. Klingel R Schaefer M Schwarting A Himmelsbach F Altes U Uhlenbusch-Korwer I Hafner G Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation Nephrol Dial Transplant 2004 19 164-170 10.1093/ndt/ gfg459 14671052
6. Salmon J Cardigan R Mackie I Cohen SL Machin S Singer M Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways Intensive Care Med 1997 23 38-43 10.1007/s001340050288 9037638
7. Wendel HP Heller W Gallimore MJ Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model Immunopharmacology 1996 32 57-61 10.1016/0162-3109(96)00009-4 8796267
8. Urano T Ihara H Suzuki Y Takada Y Takada A Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity Semin Thromb Hemost 2000 26 39-42 10.1055/s-2000-9801 10805280
9. Sandset PM Abildgaard U Pettersen M A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions Thromb Res 1987 47 389-400 10.1016/0049-3848(87)90454-3 3499007
10. Nuijens JH Huijbregts CC Eerenberg-Belmer AJ Abbink JJ Strack van Schijndel RJ Felt-Bersma RJ Thijs LG Hack CE Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis Blood 1988 72 1841-1848 3264190
11. Braat EA Dooijewaard G Rijken DC Fibrinolytic properties of activated FXII Eur J Biochem 1999 263 904-911 10.1046/j.1432-1327.1999.00593.x 10469157
12. Schousboe I Feddersen K Rojkjaer R Factor XIIa is a kinetically favorable plasminogen activator Thromb Haemost 1999 82 1041-1046 10494761
13. Himmelreich G Ullmann H Riess H Rosch R Loebe M Schiessler A Hetzer R Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device ASAIO J 1995 41 M790-M794 8573916
14. Jespersen J Munkvad S Pedersen OD Gram J Kluft C Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases Ann N Y Acad Sci 1992 667 454-456 1309069
15. Esmon CT Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation Crit Care Med 2001 29 S48-S51 10.1097/00003246-200107001-00018 11445734
16. Taylor FB Jr Chang A Hinshaw LB Esmon CT Archer LT Beller BK A model for thrombin protection against endotoxin Thromb Res 1984 36 177-185 10.1016/ 0049-3848(84)90339-6 6506035
17. Osterud B Tissue factor expression by monocytes: Regulation and pathophysiological roles Blood Coagul Fibrinolysis 1998 9 Suppl 1 S9-S14 9819023
18. Tobu M Ma Q Iqbal O Schultz C Jeske W Hoppensteadt DA Fareed J Comparative tissue factor pathway inhibitor release potential of heparins Clin Appl Thromb Hemost 2005 11 37-47 10.1177/ 107602960501100104 15678271
19. Guth HJ Klingbeil A Wiedenhoft I Rose HJ Kraatz G Presence of factor-VII and -XIII activity in ultrafiltrate during hemofiltration Int J Artif Organs 1999 22 482-487 10493555
20. Bouman CS van Olden RW Stoutenbeek CP Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes Blood Purif 1998 16 261-268 10.1159/000014343 9917534
21. Kutsogiannis DJ Gibney RT Stollery D Gao J Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Kidney Int 2005 67 2361-2367 10.1111/ j.1523-1755.2005.00342.x 15882280
22. du Cheyron D Bouchet B Bruel C Daubin C Ramakers M Charbonneau P Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: A case-control study Crit Care 2006 10 R45 1550897 16542495 10.1186/cc4853
23. de Pont AC Bouman CS de Jonge E Vroom MB Buller HR Levi M Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis Intensive Care Med 2003 29 1205 (letter). 10.1007/ s00134-003-1781-4 12761613
24. de Pont AC Oudemans-van Straaten HM Roozendaal KJ Zandstra DF Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: A double-blind, randomized, crossover study Crit Care Med 2000 28 421-425 10.1097/00003246-200002000-00022 10708177
25. Holt AW Bierer P Bersten AD Bury LK Vedig AE Continuous renal replacement therapy in critically ill patients: Monitoring circuit function Anaesth Intensive Care 1996 24 423-429 8862637
26. Knaus WA Wagner DP Draper EA Zimmerman JE APACHE II: A severity of disease classification system Crit Care Med 1985 13 519 525 4006490